ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026
Antibiotic use in patients with severe acute respiratory syndrome due to SARS-CoV-2 in a Brazilian University Hospital (2020-2021).
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic has profoundly affected healthcare systems worldwide. High and often inappropriate antimicrobial use has been reported in COVID-19 care, potentially increasing the risk of bacterial resistance and other adverse events. This study aimed to characterize and quantitatively assess antimicrobial use among Brazilian patients hospitalized with severe acute respiratory syndrome (SARS) due to SARS-CoV-2 infection. Methods: This retrospective observational cohort study included patients hospitalized with SARS caused by SARS-CoV-2 at the University Hospital of Brasília (HUB) during 2020 and 2021. Data on antimicrobial regimens, duration of therapy, and days of use were extracted from medical records. Results: The median age was 61 years (IQR, 49-72); most patients were unvaccinated against COVID-19 (76.3%), and comorbidities were highly prevalent (90.1%). Patients were stratified by clinical severity at hospital discharge: 301 (47.2%) were classified as Severe COVID-19 and 337 (52.8%) as Critical COVID-19. Greater clinical severity was consistently associated with increased antimicrobial exposure across multiple indicators, including the proportion of patients receiving antimicrobials, days of therapy (DOT), length of therapy (LOT), and the DOT/LOT ratio and an inverse association was observed for antimicrobial-free days (AFD). According to the World Health Organization (WHO) AWaRe classification, Watch-group antibiotics were most frequently prescribed (91.9% of patients); however, Reserve-group antibiotics showed the greatest increases in both frequency and duration of use with increasing disease severity. Conclusions: In this single-center Brazilian cohort, antimicrobial therapy was highly prevalent (94.4%). Higher clinical severity was strongly associated with greater antimicrobial exposure and fewer AFD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.